Lupin has aimed to improve supplies to Japan which is the second largest market for pharmaceuticals.
Mumbai-based pharma major Lupid Limited has announced that it has received approval from US Food and Drug Administration (FDA) to market Slidenafil Tablets USP, 25 mg, 50 mg, and 100 mg. Lupin’s Slidenafil is generic version of Viagra Tablets, 25 mg, 50 mg, and 100 mg, produced by Pfizer Inc.
As per a press release of Lupin, Sildenafil Tablets are phosphodiesterase-5 (PDE5) inhibitor which is used for treatment of erectile dysfunction (ED).
According to reliable sources, annual sales of Slidenafil Tablets USP, 25 mg, 50 mg, and 100 mg was approximately USD$611 million in the US.
For the record, Lupin Limited is a multinational pharmaceutical company based in Mumbai. The company manufactures and sells a wide range of branded and generic formulations, APIs, biotechnology products and Advanced Drug Delivery Systems (ADDS) globally. Key focus areas of company include cardiovascular, pediatrics, anti-infectives, asthma, nervous system, anti-tuberculosis, gastro-intestinal, and diabetology. Major markets of the company include India, United States of America, Europe, Japan, Australia, South Africa, and Philippines. In 2015, 45% of Lupin’s sales was from United States which is company’s largest market. Second largest market for Lupin was India with 24% sales, in fiscal year 2015.
Lupin has aimed to improve supplies to Japan which is the second largest market for pharmaceuticals. Lupin is already 8th largest generic pharmaceutical company in Japan.
Lupin Limited is currently down on BSE by INR 11.4, from INR 743.55 to INR 732.15, which is 1.53% less. The company has traded 14,92,211 (NSE+BSE) shares on counter so far. For FY 2018, the consolidated sales of Lupin was INR 155,598 million (US$ 2.41 billion) and net profit before exceptional items was INR 13,934 million (US$ 216 million). The current market cap of the company is INR 33,644.39 crores.
A qualified post graduate in finance and management, Pankaj Singh has been working as a content developer for quite a while now. Endowed with a two-year experience as a U.K. insurance underwriter, Pankaj pens down pieces for news.decresearch.com and other portals.